Agents for the Treatment of Alzheimer's Dementia

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a new peptide (referred to as sequence no. 1 and its derivatives) that binds specifically to toxic amyloid-beta (Aβ) oligomers, which are thought to play a key role in the development and progression of Alzheimer's disease. The invention covers the use of this peptide in pharmaceutical compositions, as a direct treatment or via gene therapy vectors that enable expression of the peptide in the human body. By binding Aβ oligomers both inside and outside neuronal cells, the peptide can reduce their toxicity, potentially stopping or reversing Alzheimer's disease progression.

Use CasesContent extracted from patent full text and abstract with AI.

• As a pharmaceutical drug directly administered to patients with Alzheimer's disease to target and neutralize toxic Aβ oligomers.
• As a gene therapy, delivering DNA or a vector into a patient's nervous system to produce the therapeutic peptide within the body.
• As a preventive measure or early intervention in patients at high risk for Alzheimer's disease, aiming to halt the formation of toxic Aβ aggregates.
• As a research tool for studying Alzheimer's disease mechanism by selectively binding and modulating Aβ oligomer populations in experimental settings.

BenefitsContent extracted from patent full text and abstract with AI.

• Targets the toxic Aβ oligomers, believed to be the main pathological agents in Alzheimer's, more specifically and effectively than existing treatments.
• Potential to both stop and reverse the progression of Alzheimer's disease, not just relieve symptoms.
• Can act both inside and outside neuronal cells, increasing the likelihood of comprehensive disease modification.
• Gene therapy options provide the possibility of long-term, persistent treatment effects from a single administration.
• Reduced likelihood of immune reactions due to human-like secretion signal sequences in modified peptides.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to agents for treating Alzheimer's disease. According to the invention, a peptide according to sequence number 1 is provided, which binds to Aß oligomers and thus leads to healing or abatement of Alzheimer's disease. In further embodiments of the invention, peptides are provided, which contain a sequence number 1 but have preceding sequence segments that enable the peptide to be secreted. For the purpose of gene therapy, corresponding DNA sequences and vectors, in particular according to sequences 3 to 6, are provided.